GeoVax Labs, Inc. (GOVX)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. David Alan Dodd
|
Chairman, President & CEO | 387.69k | -- | 1950 |
|
Dr. Mark J. Newman Ph.D.
|
Chief Scientific Officer | 301.7k | -- | 1955 |
|
Dr. Kelly T. McKee Jr., M.D., M.P.H.
|
Chief Medical Officer | 368.55k | -- | 1950 |
|
Mr. Mark W. Reynolds CPA
|
CFO & Corporate Secretary | 348.2k | -- | 1962 |
|
Mr. Thomas O'Brien
|
Vice President of Quality Systems & Compliance | -- | -- | -- |
|
Mr. Jeffrey Welch
|
Head of Process Development & Manufacturing Operations | -- | -- | -- |
|
Dr. John W. Sharkey Ph.D.
|
Vice President of Business Development | -- | -- | 1956 |
GeoVax Labs, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 19
Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
June 1, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
